[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gestational-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gestational-complications":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,60,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":39,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100636441","cardiometabolic-disease-and-substrate-metabolism-100636441",false,"NCT07565727","Cardiometabolic Disease and Substrate Metabolism","Cardiometabolic Disease, Substrate Metabolism, and Abnormal Placental Pathology: a Multimodal Maternal-Fetal Study","CAP","Inclusion Criteria:\n\n* Age 18-45\n* Any pre-pregnancy BMI\n* At least one high risk OR one moderate risk factor for pre-eclampsia based on ACOG and USPSTF guidelines\n* Willingness to adhere to aspirin therapy\n* Willingness to undergo 2h OGTT for serum collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.\n* Gestational age at enrollment \\\u003C18 weeks\n* Ability to speak, read, and communicate via English\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n* Type 1 Diabetes Mellitus\n* Current gestational diabetes mellitus\n* Current\u002Factive platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura\u002FITP, thrombotic thrombocytopenic purpura\u002FTTP, von Willebrand disease, etc.)\n* Thrombophilia\n* Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)\n* Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)\n* Current or recent use of steroids\n* Current use of prophylactic or therapeutic anticoagulation\n* Medical contraindication to aspirin therapy\n* Molar pregnancy\n* Renal disease\n* Inability or unwillingness to give informed consent\n* Current psychiatric illness\u002Fsocial situation that would limit compliance with study requirements, as determined by the principal investigators","FEMALE","18 Years","45 Years",{"count":21,"type":22},50,"ESTIMATED","9 Months","OBSERVATIONAL","This study's primary purpose is to determine the potential relationship between cardiometabolic disease, specifically insulin resistance (HOMA-IR), and maternal lipid oxidation.",[27,28,29,30,31,32,33,34,35,36,37,38],"Preeclampsia","Gestational Diabetes Mellitus (GDM)","Preeclampsia (PE)","Preeclampsia (PE) Risk","Gestational Diabetes","Gestational Diabetes Mellitus in Pregnancy","Cardiometabolic Diseases","Insulin Resistance","Placental Dysfunction","Pregnancy","Pregnancy Complications","Gestational Complications",[40,41,27,31,42,43,44,45,46],"Cardiometabolic disease","Substrate metabolism","Insulin resistance","HOMA-IR","Lipid oxidation","Placental dysfunction","Chorangiosis","RECRUITING","2026-04-27",{"date":50,"type":51},"2026-05-04","ACTUAL",{"date":53,"type":51},"2025-12-10",{"date":55,"type":22},"2027-08",{"name":57,"class":58},"University of Tennessee Graduate School of Medicine","OTHER",1,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":17,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100448470","effects-of-the-mediterranean-diet-during-pregnancy-on-the-onset-of-allergies-in-the-offspring-100448470","NCT05119868","Effects of the Mediterranean Diet During Pregnancy on the Onset of Allergies in the Offspring","Effects of the Mediterranean Diet During Pregnancy on the Onset of Allergies in the Offspring: a Multi-center Randomised-controlled Trial (the PREMEDI Project)","PREMEDI","Inclusion Criteria:\n\n\\- healthy women (aged 20-35 years), at first trimester of pregnancy, of at risk for atopy baby\n\nExclusion Criteria:\n\n* concomitant presence of infections;\n* concomitant presence of malignancies;\n* concomitant presence of major gastrointestinal malformations;\n* concomitant presence of immunodeficiencies;\n* concomitant presence of autoimmune diseases;\n* concomitant presence of chronic inflammatory bowel diseases;\n* concomitant presence of functional gastrointestinal disorders;\n* concomitant presence of celiac disease;\n* history of abdominal surgery with gastrointestinal resection;\n* concomitant presence of neuropsychiatric disorders;\n* concomitant presence of central nervous system disorders;\n* vegan diet;\n* twin pregnancy;\n* concomitant presence of genetic disorders;\n* concomitant presence of metabolic disorders.",true,"20 Years","35 Years",{"count":72,"type":22},276,"INTERVENTIONAL",[75],"NA","Allergy prevalence is increasing steadily with some describing as the \"epidemic of the twenty-first century\". Maternal diet during pregnancy has been linked to offspring allergy risk, so it represents a potential target for allergy prevention. The Mediterranean Diet (MD) is considered one of the healthiest dietary models which exerts regulatory effects on immune system, due to the synergistic and interactive combinations of nutrients. We aim to study the effects of MD in pregnancy on the onset of allergic diseases at 2 years of age in the offspring.",[78,79,38,80,81,82,83,84],"Allergies","Obesity","Gestational Weight Gain","Perinatal Condition","Birth Weight","Chronic Diseases in Children","Breast Feeding","2026-02-11",{"date":87,"type":51},"2026-02-12",{"date":89,"type":51},"2021-11-02",{"date":91,"type":22},"2026-03-10",{"name":93,"class":58},"Federico II University",2,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":102,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":59},"100577789","relationship-between-aspirin-metabolism-and-markers-of-metabolic-dysfunction-among-pregnant-persons-at-risk-of-pre-eclampsia-100577789","NCT06802861","Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia","RAMP","Inclusion Criteria:\n\n* Recommended aspirin for pre-eclampsia prevention by OB\u002FGYN or MFM specialist based on ACOG and USPSTF guidelines (1 high risk factor, 2+ moderate risk factors)\n\n  * Willingness to adhere to aspirin therapy\n  * Willingness to undergo 2h OGTT for serum and urine collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.\n  * Gestational age at enrollment \\\u003C16 weeks\n  * Ability to speak, read, and communicate via English\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n\n  * Type 1 Diabetes Mellitus\n  * Current gestational diabetes mellitus\n  * Current\u002Factive platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura\u002FITP, thrombotic thrombocytopenic purpura\u002FTTP, von Willebrand disease, etc.)\n  * Thrombophilia\n  * Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)\n  * Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)\n  * Current or recent use of steroids\n  * Current use of prophylactic or therapeutic anticoagulation\n  * Medical contraindication to aspirin therapy\n  * Molar pregnancy\n  * Renal disease\n  * Inability or unwillingness to give informed consent\n  * Current psychiatric illness\u002Fsocial situation that would limit compliance with study requirements, as determined by the principal investigators",{"count":21,"type":22},"This study's primary purpose is to determine the relationship between aspirin metabolism and markers of metabolic dysfunction among patients at risk for preeclampsia.",[27,29,30,105,36,37,31,32,38],"Obesity and Obesity-related Medical Conditions",[107,108,109,110,111,112,113,114,115],"metabolic dysfunction","gestational diabetes","pregnancy","maternal obesity","maternal insulin resistance","aspirin metabolism","GDM","substrate oxidation","gestational glucose intolerance","2025-09-03",{"date":118,"type":51},"2025-09-10",{"date":120,"type":51},"2025-01-01",{"date":122,"type":22},"2028-12-31",{"name":57,"class":58}]